Got a splitting headache? It could be all in your genes
QUT and Dutch scientists have identified two new genes involved in hemiplegic migraine, a rare, debilitating subtype of migraine that causes weakness along one side of the body during the aura phase.
First published 3 March 2023
Two new genes implicated in severe migraine subtype
Hemiplegic migraine causes weakness or paralysis on one side of the body and is generally inherited in families
Distinguished Professor Lyn Griffiths, Director of the QUT Centre for Genomics and Personalised Health, and scientists from Leiden University in the Netherlands, used genome sequencing methods to implicate a role for the two genes and published their findings in Molecular Neurobiology.
“Hemiplegic migraine (HM) is a severe subtype of migraine, usually inherited dominantly in families, where people experience significant weakness or paralysis on one side of their body, along with other serious migraine symptoms,” Professor Griffiths said.
“Using genome sequencing methods, we implicated two genes, CACNA1H and CACNA1I, which are ion channel genes involved in controlling calcium levels in the brain and potentially affecting neurotransmitter release.
“Research suggests that HM, may be regarded as a complex disorder with multiple genetic factors. Already there are three known causally implicated genes for familial hemiplegic migraine.
“It has also been hypothesised that a complex disorder can be the result of an accumulation of genetic variants in a disease pathway, where the crossing of a certain threshold leads to disease.”
Professor Griffiths said current evidence indicated that complex traits were likely to be underpinned by a combination of both common and rare variants.
“Our study found that hemiplegic migraine was associated with an increased burden of mutations in the number of variants in the CACNA1H and CACNA1I genes
“These genes can modify HM disease risk, which supports the hypothesis that the disease may have complex heritability, in addition to the strictly single gene forms.
“This study adds to our knowledge of the modification of risk by mutations in several other genes previously identified in some HM patients. These genes implicated in HM are mainly associated with disorders of transport of various substances across brain membranes.”
Professor Griffiths said further studies published in Frontiers in Molecular Neuroscience, investigated the role of identified mutations in the CACNAII gene and confirmed that there were functional effects of CACNA1I variants on electrophysiological properties.
“These studies investigated five implicated mutations and showed numerous functional alterations across the channels, further suggesting that variants identified in CACNA1I could play a causative or contributory role in HM.”
This functional research was conducted by Professor Griffiths and her team, in collaboration with national and international scientists from the University of Wollongong and the Institute of Molecular Medicine at the University of Oxford.
QUT scientists have uncovered functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive prostate cancers and the level of treatment the patient needs.